BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36719788)

  • 1. Predictive Models for Human Cytochrome P450 3A7 Selective Inhibitors and Substrates.
    Xu T; Kabir M; Sakamuru S; Shah P; Padilha EC; Ngan DK; Xia M; Xu X; Simeonov A; Huang R
    J Chem Inf Model; 2023 Feb; 63(3):846-855. PubMed ID: 36719788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7.
    Godamudunage MP; Grech AM; Scott EE
    Drug Metab Dispos; 2018 Sep; 46(9):1329-1337. PubMed ID: 29991575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.
    Kabir M; Padilha EC; Shah P; Huang R; Sakamuru S; Gonzalez E; Ye L; Hu X; Henderson MJ; Xia M; Xu X
    Front Pharmacol; 2022; 13():899536. PubMed ID: 35847040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 3A: ontogeny and drug disposition.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Work HM; Kandel SE; Lampe JN
    Drug Metab Dispos; 2024 May; ():. PubMed ID: 38702193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
    Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
    Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
    Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
    Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.
    Li H; Lampe JN
    Arch Biochem Biophys; 2019 Sep; 673():108078. PubMed ID: 31445893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
    Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
    Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
    Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
    Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental regulation of CYP3A4 and CYP3A7 in Chinese Han population.
    He H; Nie YL; Li JF; Meng XG; Yang WH; Chen YL; Wang SJ; Ma X; Kan QC; Zhang LR
    Drug Metab Pharmacokinet; 2016 Dec; 31(6):433-444. PubMed ID: 27727071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
    Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
    Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulatory and Inhibitory Effects of Steroid Hormones and Human Cytochrome P450 (CYP) 3A Inhibitors on Cortisol 6β-Hydroxylation Catalyzed by CYP3A Subfamilies.
    Niwa T; Tani M; Suzuki A; Murakami M
    Drug Metab Bioanal Lett; 2023; 16(2):73-80. PubMed ID: 37649294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers.
    Vyhlidal CA; Bi C; Ye SQ; Leeder JS
    Drug Metab Dispos; 2016 Jul; 44(7):1020-6. PubMed ID: 26772622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Study of Binding Pockets in Human CYP1A2, CYP3A4, CYP3A5, and CYP3A7 with Aflatoxin B1, a Hepato-Carcinogen, by Molecular Dynamics Simulation & Principal Component Analysis.
    Saba N; Seal A
    Curr Drug Metab; 2022; 23(7):521-537. PubMed ID: 35850656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.